L3VLUP
ProSign in

A · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ALLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • A
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterALLY
Q3 202018 holders, $7.1bn33 holders, $14.1bn
Q4 202017 holders, $7.8bn29 holders, $17.3bn
Q1 202120 holders, $7.2bn24 holders, $23.0bn
Q2 202119 holders, $8.5bn24 holders, $27.8bn
Q3 202122 holders, $8.5bn31 holders, $29.9bn
Q4 202122 holders, $8.5bn31 holders, $34.7bn
Q1 202224 holders, $6.8bn24 holders, $35.3bn
Q2 202224 holders, $6.5bn33 holders, $42.7bn
Q3 202219 holders, $4.5bn31 holders, $43.4bn
Q4 202224 holders, $6.2bn31 holders, $46.6bn
Q1 202327 holders, $6.0bn33 holders, $44.3bn
Q2 202321 holders, $4.7bn37 holders, $59.6bn
Q3 202321 holders, $4.0bn44 holders, $67.6bn
Q4 202316 holders, $4.9bn45 holders, $73.6bn
Q1 202412 holders, $5.3bn41 holders, $95.3bn
Q2 202413 holders, $4.2bn43 holders, $110bn
Q3 202416 holders, $4.9bn45 holders, $107bn
Q4 202417 holders, $4.3bn46 holders, $93.9bn
Q1 202517 holders, $3.8bn42 holders, $98.4bn
Q2 202513 holders, $3.8bn43 holders, $93.2bn
Q3 202515 holders, $3.9bn39 holders, $86.7bn
Q4 202517 holders, $4.6bn41 holders, $123bn
Q1 202621 holders, $4.0bn39 holders, $106bn
Q2 202615 holders, $5.1bn44 holders, $132bn
A

Agilent Technologies Inc

Holders
21
Reported value
$4.0bn
Buyers
16
Sellers
21

Breadth -5 among 91 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUP
LLY

Eli Lilly & Co

Holders
39
Reported value
$106bn
Buyers
25
Sellers
25

Breadth 0 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 44 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only A (5)

Balyasny Asset Management LLC, Freestone Grove Partners LP, MFS Investment Management, Quantbot Technologies LP, Winton Group Ltd

Only LLY (23)

Acadian Asset Management LLC, ARK Investment Management LLC, Artisan Partners LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Dodge & Cox, Fidelity (FMR LLC), GAMCO Investors Inc, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, Point72 Asset Management LP, Polen Capital Management LLC, Soros Fund Management LLC, T. Rowe Price Associates Inc, Walleye Capital LLC, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →